Two great papers, recently published in European Urology, confirm that MRI-targeted biopsy is the attractive and reliable diagnostic strategy for prostate cancer compared to the traditional diagnostic pathway of systematic TRUS biopsy.

New strong clinical data for Sonablate HIFU, recently published in the BJU International, confirms very promising medium-term oncological outcomes.

At the AUA congress in Chicago, Prof. Leonard Marks and the UCLA group presented a method for focal HIFU, employing multiparametric magnetic resonance imaging, fusion biopsy, margin generation, and targeted treatment.

We are delighted to announce a new partnership with OTU Medical Inc., a Silicon Valley based medical technology company, which recently received the EU approval for its second generation WiScope® single-use flexible digital ureteroscope.

We’re pleased to announce that the Prostate Imaging and Focal Therapy Masterclass, presented by one of the world’s leading urologists and experts in focal therapy, Prof. Hashim Ahmed, Chair of Urology of Imperial College London, will be returning on the 5-6th April 2019 for its second event.

SonoIQ, a small pocket Ultrasound, transfers high resolution ultrasound images to Android, iOS or Windows smartphone or tablet via WiFi or USB cable.

We are happy to share with you a new study about Gold Anchor from the Karolinska University Hospital in Stockholm, Sweden.
Conclusion of the study: The use of thin needles for the implantation of fiducials appears to reduce the rate of infection despite the use of a single dose of non-broad-spectrum antibiotics as prophylaxis. The marker construct appears to provide stability in the tissues.

The UK urologist group led by University College and Imperial College London published 5-year outcomes from a multicenter study following focal therapy treatment with its Sonablate technology of 625 medium to high-risk clinically significant nonmetastatic prostate cancer patients.